Overview
About Apellis Pharmaceuticals
At Apellis, we are committed to developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. Our work is rooted centrally at C3, which is the only target in the complement cascade that addresses all three pathways that can drive disease. Targeting C3 has broad platform potential to treat many diseases where patients have few or no treatment options available. Our programs across ophthalmology, nephrology, hematology, and neurology are further exploring what is possible by targeting C3. You can view our community guidelines here: Community guidelines: http://bit.ly/476Q8
Headquarters
Waltham, MAWebsite
https://apellis.com/Company Size
501-1,000 employeesIndustry
Biotechnology ResearchCompany Type
Public CompanyFounded
2008Specialties
Targeted C3 Therapies, Complement System, Hematology, Ophthalmology, Nephrology, Paroxysmal Nocturnal Hemoglobinuria (PNH), Geographic Atrophy (GA), C3 Glomerulopathy (C3G), Gene Therapy, and NeurologyJobs

Medical Science Liaison - New South Wales, Queensland
Apellis Pharmaceuticals
Australia

Product Manager, US Professional Education
Apellis Pharmaceuticals
Waltham, MA

Senior Director, Medical Safety Science
Apellis Pharmaceuticals
Waltham, MA

Associate Director, Tech Ops
Apellis Pharmaceuticals
Waltham, MA

Vice President, Value, Access and Policy
Apellis Pharmaceuticals
Waltham, MA